Drug Type Small molecule drug |
Synonyms- |
Target |
Action modulators |
Mechanism S1PR2 modulators(Sphingosine 1-phosphate receptor Edg-5 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cardiovascular Diseases | Discovery | - | 28 Jun 2024 | |
| Digestive System Disorders | Discovery | - | 28 Jun 2024 | |
| Endocrinology and Metabolic Disease | Discovery | - | 28 Jun 2024 | |
| Immune System Diseases | Discovery | - | 28 Jun 2024 | |
| Infectious Diseases | Discovery | - | 28 Jun 2024 | |
| Neoplasms | Discovery | - | 28 Jun 2024 | |
| Nervous System Diseases | Discovery | - | 28 Jun 2024 | |
| Other Diseases | Discovery | - | 28 Jun 2024 | |
| Pulmonary Disease, Chronic Obstructive | Discovery | - | 28 Jun 2024 | |
| Retinitis | Discovery | - | 28 Jun 2024 |





